Aimmune therapeutics, inc. (AIMT)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Operating expenses
Research and development

123,987

133,420

89,325

54,642

19,816

8,181

3,495

General and administrative

125,817

81,921

43,949

26,885

16,181

2,951

1,263

Total operating expenses

249,804

215,341

133,274

81,527

35,997

11,132

4,758

Loss from operations

-249,804

-215,341

-133,274

-81,527

-35,997

-11,132

-4,758

Interest income

5,851

4,984

2,190

-

-

-

-

Interest expense

4,916

113

114

-

-

-

91

Interest income, net

1,088

-221

-71

703

181

12

24

Loss before provision for income taxes

-247,781

-210,691

-131,269

-80,824

-35,816

-11,120

-4,825

Provision for income taxes

716

61

56

-

-

0

-

Net loss

-248,500

-210,752

-131,325

-80,824

-35,816

-11,120

-4,825

Other comprehensive loss, net of tax:
Unrealized gain on available-for-sale investments

188

-

-81

61

-88

0

-

Comprehensive loss

-248,309

-210,752

-131,406

-80,763

-35,904

-11,120

-4,825

Net loss per share, basic and diluted

-3.97

-3.67

-2.61

-1.89

-1.88

-3.80

-1.65

Weighted average shares used in computing net loss per common share, basic and diluted

62,558

57,403

50,401

42,751

19,041

2,929

2,926